Elena Ridloff

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Founded in 1991 by Dr. Lindsay Rosenwald, Paramount BioCapital Asset Management, Inc. is a hedge fund manager located in New York City. The firm is a subsidiary of Paramount BioCapital, Inc.

Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors.

BioVision, Inc. manufactures pharmaceutical products for apoptosis and cell signaling. It offers assay kits, antibodies, and recombinant proteins and enzymes. The company is headquartered in Milpitas, CA.

Part of Stealth BioTherapeutics Corp., Stealth BioTherapeutics, Inc. develops therapies to treat mitochondrial dysfunctions and age-related diseases. The private company is based in Newton, MA. The company was founded in 2007. Irene P. McCarthy has been the CEO of the company since 2009.

Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan.